Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
Different homologous and heterologous vaccination regimens have been used for COVID-19. Here the authors show in a cohort analysis from Catalonia that heterologous vaccination with ChAdOx1 followed by BNT162b2 has better vaccine effectiveness than two doses of ChAdOx1.
Збережено в:
| Автори: | , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Nature Portfolio
2022-03-01
|
| Серія: | Nature Communications |
| Онлайн доступ: | https://doi.org/10.1038/s41467-022-29301-9 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|